Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer.

We reviewed our initial institutional experience with the use of stereotactic hypofractionated radiation therapy (SFRT) in patients with stage I non-small cell lung cancer (NSCLC). Thirty patients with inoperable stage I non-small cell lung cancer due to a severe chronic obstructive pulmonary disease (COPD) and/or chronic heart disease (Eastern Cooperative Oncology Group (ECOG) performance status of 0-2) were treated between December 2000 and October 2003 with SFRT in curative intent. Infiltration of locoregional lymph nodes and distant metastases were ruled out by computerized tomography (CT) scan of the brain, thorax, and abdomen, and by whole body FDG-positron emission tomography scan in all patients. Total RT doses ranged from 24.0 to 37.5 Gy, given in 3-5 fractions to the 60% isodose encompassing the planning target volume. Immobilization was carried out by a vacuum couch and a low-pressure foil. The clinical target volume was the tumor as it appeared in lung windowing on lung CT scan. Organ movements (caused by breathing; range, 6-22 mm) and reproducibility of patient positioning in the couch (range, 3-12 mm) were calculated by sequential CT and orthogonal films. The individual values were taken into account as a safety margin for the definition of the planning target volume (PTV). The median follow-up of living patients is 18 months (range, 6-38 months). As maximum response, there were 10 (33%) complete responses (CRs) and 14 (47%) partial responses (PRs), resulting in a total response rate of 80%. Stable disease was observed in 6 (20%) patients, while no patient experienced progressive disease. During follow-up, 2 (7%) local recurrences were observed (after 17 and 18 months, respectively). Of 5 (17%) patients who developed distant metastasis, 1 patient developed it in liver (3 months), another one in brain (6 months), and another one in the lung (36 months), while 2 patients developed it in mediastinal lymph nodes (after 8, and 11 months, respectively) only. Of 9 (30%) patients who have died, only 3 (10%) died of cancer, while 6 (20%) died of cancer-unrelated or unknown causes. Acute side effects were mild and affected 9 (33%) patients during the RT course (fatigue being the most frequent one in 6 patients). There were 22 acute events occurring in 19 (63%) patients during the first 3 months post-SFRT, the most frequent one being pneumonitis observed in 14 (46%) patients. However, there was only one (3%) grade 3 acute toxicity and no patient experienced greater than grade 3 toxicity during this study. One (3%) patient experienced rib fracture as the late event. SFRT is a feasible and safe treatment method in inoperable patients with stage I NSCLC having reduced lung capacity. Longer follow-up is necessary to get robust data on late toxicity as well as survival.

[1]  Angelika Hoess,et al.  Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer (NSCLC). , 2003, International journal of radiation oncology, biology, physics.

[2]  I. Lax,et al.  Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. , 1995, Acta oncologica.

[3]  M. Nishimura,et al.  Small‐volume image‐guided radiotherapy using hypofractionated, coplanar, and noncoplanar multiple fields for patients with inoperable Stage I nonsmall cell lung carcinomas , 2002, Cancer.

[4]  Shinichi Shimizu,et al.  Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. , 2003, International journal of radiation oncology, biology, physics.

[5]  Quynh-Thu Le,et al.  Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. , 2003, The Annals of thoracic surgery.

[6]  Y. Shibamoto,et al.  Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. , 2001, International journal of radiation oncology, biology, physics.

[7]  K. Suemasu,et al.  Radiotherapy in inoperable stage I lung cancer. , 1991, Japanese journal of clinical oncology.

[8]  B. Jeremic,et al.  Radiotherapy alone in technically operable, medically inoperable, early-stage (I/II) non-small-cell lung cancer. , 2002, International journal of radiation oncology, biology, physics.

[9]  P. Black,et al.  Stereotactic radiotherapy for pediatric and adult brain tumors: preliminary report. , 1994, International journal of radiation oncology, biology, physics.

[10]  Stephanie Frost,et al.  Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. , 2003, Chest.

[11]  S. Yoon,et al.  Preliminary Results of Stereotactic Body Frame Based Fractionated Radiosurgery on Consecutive Days for Primary Lung Cancer or Metastatic Lung Tumors. , 2002 .

[12]  Michael Flentje,et al.  Stereotactic Radiotherapy of Targets in the Lung and Liver , 2001, Strahlentherapie und Onkologie.

[13]  B. Jeremic,et al.  Hyperfractionated radiotherapy for clinical stage II non-small cell lung cancer. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  S. Singletary,et al.  Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. , 2000, International journal of radiation oncology, biology, physics.

[15]  Wan Ariffin Bin Abdullah,et al.  Med Pediatr Oncol , 1999 .

[16]  C. Mountain The new International Staging System for Lung Cancer. , 1986, The Surgical clinics of North America.

[17]  L D Lunsford,et al.  A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. , 1994, International journal of radiation oncology, biology, physics.

[18]  Takashi Aruga,et al.  Stereotactic single high dose irradiation of lung tumors under respiratory gating. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  John W Hopewell,et al.  Radiation-therapy effects on bone density. , 2003, Medical and pediatric oncology.

[20]  H M Kooy,et al.  Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. , 1995, Journal of the National Cancer Institute.

[21]  J. Wong,et al.  Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. , 2001, International journal of radiation oncology, biology, physics.

[22]  M Bellerive,et al.  Adaptation and verification of the relocatable Gill-Thomas-Cosman frame in stereotactic radiotherapy. , 1994, International journal of radiation oncology, biology, physics.

[23]  W. Curran,et al.  Clinical stage II non‐small cell lung cancer treated with radiation therapy alone:The significance of clinically staged ipsilateral hilar adenopathy (N1 disease) , 1992, Cancer.

[24]  O. Pastyr,et al.  Stereotactic percutaneous single dose irradiation of brain metastases with a linear accelerator. , 1987, International journal of radiation oncology, biology, physics.

[25]  R. Tsuchiya,et al.  Prognosis and survival in resected lung carcinoma based on the new international staging system. , 1988, The Journal of thoracic and cardiovascular surgery.

[26]  P. Black,et al.  Fractionated stereotactic radiotherapy for the treatment of acoustic neuromas: preliminary results. , 1996, International journal of radiation oncology, biology, physics.

[27]  Seung Do Ahn,et al.  Stereotactic body frame based fractionated radiosurgery on consecutive days for primary or metastatic tumors in the lung. , 2003, Lung cancer.

[28]  B. Jeremic,et al.  Hyperfractionated radiotherapy alone for clinical stage I nonsmall cell lung cancer. , 1997, International journal of radiation oncology, biology, physics.

[29]  B. Jeremic,et al.  Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy alone. , 2003, Lung cancer.

[30]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[31]  G. Tsumatori,et al.  Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients , 1998, Cancer.